Abstract 3984
Background
Studies describe that up to 90 % of all patients develop chemotherapy induced peripheral neuropathy (CIPN) during and after treatment for colorectal cancer with the chemotherapeutic drug oxaliplatin. Patients may struggle with CIPN many years after treatment completion, and in worst case live with it permanently with deep impact on their everyday life. Until date, there is no treatment to prevent or treat CIPN. Thus, it is urgent to understand the influence of CIPN and detect early signs of this side effect. Still, no golden standard method of assessment and evaluation of CIPN exists. The study aims to answer: 1. What questionnaire is deemed suitable by patients and nurses regarding reporting and sharing the experience of side effects during and after oxaliplatin treatment? 2. How does chemotherapy CIPN progresses and impact everyday life among patients receiving oxaliplatin from initiation of adjuvant chemotherapy until 3 years follow up? 3. How do patients experience and cope with CIPN and how does it influence on their perception of body and self in everyday life during and after adjuvant chemotherapy for colorectal cancer?
Methods
The study applies a multi-methods design. To ensure the practicability and meaningfulness of the questionnaire, the questionnaire are chosen in collaboration with patients and nurses in the clinical setting. Two questionnaires are tested; functional assessment of cancer treatment gynecological oncology group neurotoxicity (FACT/GOG-Ntx) and Oxaliplatin associated neurotoxicity questionnaire (OANQ). To explore a more precise and a common understanding and perception of the grade of CIPN, a three-year follow up with the chosen questionnaires will be conducted. The patients’ experiences of side effects are explored within a phenomenological frame of reference and individual in-depth interviews.
Results
The study contributes to identification of early and late signs of CIPN and provides insight into the challenges patients experience. It may assist healthcare providers to address the specific needs of these patients.
Conclusions
The study is ongoing.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Marlene Ægidiussen Jensen.
Funding
The Novo Nordisk Foundation - Nursing research.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4822 - Efficiacy of different nutritional intervention on nutritional status and quality of life for local advanced nasopharyngeal carcinoma patients: a prospective clinical trial
Presenter: Yuan-yuan Chen
Session: Poster Display session 3
Resources:
Abstract
2628 - Apatinib in treating patients with platinum-resistant or platinum-refractory recurrent or metastatic nasopharyngeal carcinoma
Presenter: Changjuan Tao
Session: Poster Display session 3
Resources:
Abstract
4887 - Impact of tumor site and adjuvant radiotherapy on survival of adenoid cystic carcinoma: a SEER database analysis
Presenter: Jason Tasoulas
Session: Poster Display session 3
Resources:
Abstract
2634 - Efficacy and safety of anlotinib for patients with recurrent and/or metastatic salivary gland carcinomas
Presenter: Wen Jiang
Session: Poster Display session 3
Resources:
Abstract
3568 - ACCURACY a phase (P) 2 trial of AL101, a pan-Notch inhibitor, in recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC) patients (pts) with Notch activating mutations (Notch act mut): preliminary safety and efficacy data.
Presenter: Renata Ferrarotto
Session: Poster Display session 3
Resources:
Abstract
683 - Pathologic Staging Changes in Oral Cavity Squamous Cell Carcinoma—Stage Migration and Implications for Adjuvant Treatment
Presenter: Zain Husain
Session: Poster Display session 3
Resources:
Abstract
563 - Expression of immune response biomarkers in head and neck squamous cell carcinoma (HNSCC) in irradiated area
Presenter: Carole Pflumio
Session: Poster Display session 3
Resources:
Abstract
4030 - HLA-Ligandome analysis reveals target antigens of oropharyngeal squamous cell carcinoma
Presenter: Simon Laban
Session: Poster Display session 3
Resources:
Abstract
2979 - Topographical distribution of sentinel lymph nodes in early tongue squamous cell carcinomas
Presenter: Hiroyuki Goda
Session: Poster Display session 3
Resources:
Abstract
3517 - Role of follow-up (FU) FDG-PET/CT (FU-FDG-PET/CT) in patients with locoregionally advanced squamous cell carcinoma of the head and neck (LA-HNSCC) treated with chemotherapy and radiotherapy (RT), either concurrent (CRT) or sequential (ST).
Presenter: Bert Van Den Heuvel
Session: Poster Display session 3
Resources:
Abstract